Pharma Sector Check – U.S. FDA Regulatory Risk Remains Unabated: Motilal Oswal


BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

In this note, we have analysed the developments on the U.S. Food and Drug Administration inspection front at the global level and in India in particular.

The pace of U.S. FDA inspections is already increasing in the U.S. (50% of its pre-Covid five-year average in the 11-months ending August 2022 versus 31% of its pre-Covid five-year average for the 12-months ending September 2021).

We expect the number of U.S. FDA inspections to improve gradually in geographies other than the U.S. as well.

In fact, India had 38 U.S. FDA inspections over the past 12-months, with 18 sites awaiting citation from the U.S. FDA.

Regulatory compliance from the U.S. FDA continues to pose a risk to Indian pharma companies having an exposure to U.S. generics, with 60 official action indicated citations yet to be resolved.

Click on the attachment to read the full report:


This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.


Source link

What is your reaction?

In Love
Not Sure

You may also like

Comments are closed.

More in:Business